Enhances Efficiency and Reduces Treatment Time
WAYLAND, MA, Sept. 3, 2013 /CNW/ - Syneron Medical Ltd. (NASDAQ:ELOS), the leading global aesthetic device company, announced today the market launch of new applicators with expanded spot sizes for two of its best-selling platforms, Gentle Pro™ Laser Hair Removal and elos Plus® systems.
Syneron continues to innovate and respond to customer demands for efficacious treatments that reduce procedure times while enhancing patient comfort. The next generation of applicators drastically decreases the time needed to complete a procedure while maintaining an exceptional safety profile and ensuring efficacious results.
For the Syneron Candela Gentle Pro laser hair removal series, there is a new, proprietary Large Spot Delivery System (LSDS) handpiece featuring 20, 22 and 24-mm spot sizes. The new handpiece pioneers the first and only 24-mm treatment spot with the Dynamic Cooling Device (DCD) cryogen-cooling component that protects the skin's surface for maximum patient comfort.
This unique delivery system is designed to increase efficiency for both the practitioner and consumer, reducing treatment time by 30% while providing safe, comfortable and effective hair removal for all skin types. Ideal for larger areas like the legs and back, the LSDS enables trained practitioners to treat a full back in as little as 20 minutes, significantly increasing the patient flow and revenues potential for the doctor. "The larger spot sizes shrink treatment time without compromising the quality of the hair removal," said Dermatologist Anne Chapas, MD, at Union Square Laser Dermatology, New York. "Patients love it - it's comfortable, it eliminates hair quickly and can be used with the alexandrite or Nd:YAG wavelength so I can safely treat all skin tones."
"Historically, patients with darker skin tones were not ideal candidates for laser hair removal with shorter wavelength systems due to increased risk of pigment changes. This is not so with the GentleMax Pro laser system. Delivering both Alexandrite and Nd:YAG energies the GentleMax Pro provides two safe and effective wavelengths that are gentle on the skin surface while destroying hair follicles for long lasting results," adds Chapas.
Syneron's elos Plus system also received an upgrade with the introduction of four new applicators - the SRA Plus™, the SRA Mini™, the SR Plus™ for skin rejuvenation and the Motif HR Plus™ for fast hair removal. Once again, Syneron offers a wider range of spot sizes and treatment capabilities for the customer while optimizing treatment time, efficacy and overall comfort for the patient. For over ten years, the elos® combination of optical energy and bi-polar radio frequency has provided a revolutionary treatment option for the most in-demand aesthetic applications that is safe and effective for patients of all skin types. Now, the same breakthrough technology has been enhanced for the next generation with upgraded elos Plus applicators.
The new 14x35 mm spot size on the SR, SRA and Motif HR Plus have a 60% larger treatment area with a significantly smaller hand piece, significantly improving ergonomics and usability. These new applicators significantly reduce treatment time and enhance overall efficacy and patient comfort. The new SRA Plus Mini features a 15x14mm spot size for smaller, more focused treatment areas.
"The new elos Plus large applicators reduce our procedure time by one third on the face and by half to two thirds for large body areas," said Dermatologist Amy Taub, MD, of Advanced Dermatology, Glencoe and Lincolnshire, IL. "With them, we are able to complete extremely effective and comfortable treatments that deliver excellent outcomes and a high safety profile."
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE: Syneron Medical Ltd.
For further information:
The Ruth Group
Chief Financial Officer
Syneron Medical - Public Relations